Credit Suisse Downgrades Becton, Dickinson and Co (BDX) to Neutral
More News related to BDX
- Citi Starts Beckton Dickinson (BDX) at Buy, $85 Price Target
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- Becton, Dickinson (BDX) Boosts Qtr. Dividend by 12.1%, Authorizes 10M Share Buyback
- BD Board Increases Dividend and Authorizes Additional Share Repurchases
- Notable Mergers and Acquisitions of the Day 11/23: GMCR/DDRX, PBCT/FIF, CIEN, BDX, IDTI
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Credit Suisse downgrades Becton, Dickinson and Co (NYSE: BDX) from Outperform to Neutral.
Becton, Dickinson and Company (BD), is a medical technology company engaged in the manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public.
Related Categories
DowngradesStocks Mentioned
+0.74Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
